ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: A majority of CML patients present in the chronic phase (CP‐CML), where ABL1 tyrosine kinase inhibitors (TKIs) have revolutionised disease therapy, turning it from a lethal disease into a manageable condition for most patients.